Gilead Sciences, Inc. (GILD) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
GILD Revenue Growth
Revenue Breakdown (FY 2024)
GILD's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
GILD Revenue Analysis (2013–2024)
As of May 6, 2026, Gilead Sciences, Inc. (GILD) generated trailing twelve-month (TTM) revenue of $29.44 billion, reflecting modest growth of +4.7% year-over-year. The most recent quarter (Q4 2025) recorded $7.92 billion in revenue, up 2.0% sequentially.
Looking at the longer-term picture, GILD's 5-year compound annual growth rate (CAGR) stands at +5.1%, indicating steady revenue expansion. The company achieved its highest annual revenue of $32.64 billion in 2015.
Revenue diversification analysis shows GILD's business is primarily driven by Products, Other HIV (75%), Cell Therapy Products, Total Cell Therapy Product Sales (9%), and Veklury (7%). With over half of revenue concentrated in Products, Other HIV, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ABBV (+8.6% YoY), BMY (+1.8% YoY), and AMGN (+9.1% YoY), GILD has underperformed the peer group in terms of revenue growth. Compare GILD vs ABBV →
GILD Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| GILDCurrent | $29.4B | +4.7% | +5.1% | 5.8% | |
 ABBV | $61.2B | +8.6% | +6.0% | 32.8% | |
 BMY | $48.2B | +1.8% | +2.5% | 26.3% | |
 AMGN | $36.7B | +9.1% | +7.6% | 29.1% | |
 BIIB | $9.8B | +0.4% | -6.1% | 19.1% | |
 REGN | $14.3B | +5.9% | +11.0% | 24.9% |
GILD Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $28.75B | +6.0% | $22.50B | 78.3% | $1.66B | 5.8% |
| 2023 | $27.12B | -0.6% | $20.62B | 76.0% | $7.61B | 28.0% |
| 2022 | $27.28B | -0.1% | $21.62B | 79.3% | $7.33B | 26.9% |
| 2021 | $27.30B | +10.6% | $20.70B | 75.8% | $9.92B | 36.3% |
| 2020 | $24.69B | +10.0% | $20.12B | 81.5% | $4.07B | 16.5% |
| 2019 | $22.45B | +1.5% | $17.77B | 79.2% | $4.29B | 19.1% |
| 2018 | $22.13B | -15.2% | $17.27B | 78.1% | $8.20B | 37.1% |
| 2017 | $26.11B | -14.1% | $21.74B | 83.3% | $14.12B | 54.1% |
| 2016 | $30.39B | -6.9% | $26.13B | 86.0% | $17.63B | 58.0% |
| 2015 | $32.64B | +31.1% | $28.63B | 87.7% | $22.19B | 68.0% |
Full GILD Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Should I Buy GILD Right Now?
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
See GILD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GILD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GILD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGILD — Frequently Asked Questions
Quick answers to the most common questions about buying GILD stock.
Is GILD's revenue growth accelerating or slowing?
GILD revenue growth slowed to +4.7%, below the 5-year CAGR of +5.1%. TTM revenue is $29.4B. The deceleration marks a shift from historical growth rates.
What is GILD's long-term revenue growth rate?
Gilead Sciences, Inc.'s 5-year revenue CAGR of +5.1% reflects the variable expansion pattern. Current YoY growth of +4.7% is near this long-term average.
How is GILD's revenue distributed by segment?
GILD reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.